The UK biotech sector faced significant financial challenges in 2025, leading to concerns about its global competitiveness. Despite these hurdles, there are promising signs that mergers and acquisitions (M&A) activity, alongside strategic trade agreements, could pave the way for recovery.
Declining Financial Landscape
In 2025, UK biotechs experienced a substantial decline in both equity financing and venture capital investments. According to the BioIndustry Association (BIA), equity financing fell by 49%, while venture capital decreased by 13% compared to the previous year. This trend raised alarms about the UK’s attractiveness as a destination for life sciences investment, especially given its wealth of scientific expertise and robust early-stage companies.
The total funding secured by UK biotechs amounted to £1.9 billion ($2.59 billion), a stark drop from £3.7 billion ($5.05 billion) in 2024. This decline highlights a broader global downturn in biotech funding, but the UK’s situation is particularly concerning due to its strong academic and research foundations.
The IPO Drought
The absence of initial public offerings (IPOs) in 2025 further underscores the sector’s stagnation. This marked the third consecutive year without new biotech listings in the UK. IPO activity often serves as an indicator of economic health and investor confidence, and the continued lack of new entries suggests a challenging landscape for innovation and growth.
Jane Wall, managing director of the BIA, noted the precarious geopolitical climate influencing investment flows. She emphasized the need for the UK government to bolster support for this vital sector, urging domestic investors to engage more actively while also welcoming foreign capital.
Signs of Hope
Despite the prevailing challenges, there were encouraging developments that hinted at a potential resurgence in 2026. In March, Isomorphic Labs, a UK-based firm focused on AI-driven drug discovery, raised $600 million in its inaugural external funding round, bolstered by support from Google. Similarly, Verdiva Bio secured $410 million in a Series A financing round dedicated to advancing its portfolio of obesity treatments.
A notable uptick in M&A activity during the fourth quarter of 2025 highlighted a renewed appetite for investment within the small and medium-sized enterprise (SME) ecosystem. This trend was exemplified at the start of 2026 when Amgen announced its acquisition of Dark Blue Therapeutics for $840 million. Dark Blue, which specializes in oncology, has developed innovative therapeutics including a promising protein degrader targeting specific leukemia translocations.
Regulatory and Trade Dynamics
The UK government recognizes the critical importance of the pharmaceutical industry to its long-term economic strategy, contributing approximately £17.6 billion ($24.04 billion) in direct gross value added to the economy annually. However, there remains a disconnect between major pharmaceutical companies and governmental priorities. A recent example is MSD’s decision to halt a £1 billion ($1.36 billion) expansion plan in London due to misaligned commercial interests.
In December 2025, the UK secured a landmark trade agreement with the US, establishing a zero-rate tariff on pharmaceuticals exported to America. This deal is projected to safeguard approximately £5 billion ($6.83 billion) in trade and could serve as a catalyst for growth in the UK’s life sciences sector.
Future Investments
Chris Boerner, CEO of Bristol-Myers Squibb (BMS), expressed optimism, indicating that the company expects to invest over $500 million in the UK over the next five years, spurred by government commitments and a focus on innovative medicines. This investment highlights the potential for the UK to regain its status as a leader in life sciences.
Healthcare analyst Edita Hamzic noted that the zero-tariff access to the US, coupled with favorable domestic pricing, positions the UK advantageously for attracting clinical trials, early product launches, and high-value manufacturing opportunities.
Activation of Capital
The BIA’s report underscores an urgent need to mobilize the “sticky” capital currently sidelined in order to support the next wave of UK biotech startups and scale-ups. The groundwork for growth is established, but action is necessary to catalyze investment and innovation.
Conclusion
The year 2025 posed significant challenges for UK biotechs, yet the emergence of M&A activity and strategic trade agreements offers a glimmer of hope for revitalization. The potential for recovery hinges on collaborative efforts from both the government and investors to harness the sector’s inherent strengths. With the right support, the UK biotech landscape could not only recover but thrive in the coming years.
- Equity financing for UK biotechs dropped 49% in 2025.
- No IPOs occurred in the UK biotech sector for three consecutive years.
- Isomorphic Labs raised $600 million, indicating potential for innovation.
- The UK secured a zero-rate tariff deal with the US, protecting £5 billion in trade.
- Major pharmaceutical investments are anticipated in the UK due to favorable conditions.
Read more → www.pharmaceutical-technology.com